Brief: Pepgen Announces First Patient Dosed In Trial For Duchenne Muscular Dystrophy Treatment

PepGen

08/01/2024 14:04

Jan 8 (Reuters) - PepGen Inc  PEPG.O :
    * PEPGEN ANNOUNCES FIRST PATIENT DOSED IN CONNECT1-EDO51
PHASE 2
CLINICAL TRIAL OF PGN-EDO51 FOR DUCHENNE MUSCULAR DYSTROPHY
PATIENTS AMENABLE TO EXON 51 SKIPPING
    * PEPGEN INC - PRELIMINARY DATA FROM 5 MG/KG PGN-EDO51 DOSE
LEVEL
IN CONNECT1-EDO51 PHASE 2 TRIAL ARE EXPECTED MID-2024

Source text for Eikon:  ID:nGNXd3Cc4 
Further company coverage:  PEPG.O 

 ((Reuters.Briefs@thomsonreuters.com;))